老年前列腺癌的核医学影像:PET/CT应用概述
随着预期寿命延长,老年恶性肿瘤诊治日益常见,前列腺癌尤为高发。PET/CT耐受性良好,可全程准确评估肿瘤范围,18F-Flucyclovine与68Ga-PSMA是临床最常用且最具前景的两种显像剂,本文对其在老年患者中的应用进行概述。
要点
- 老年前列腺癌患者需准确评估风险获益比,功能影像如PET/CT有助于临床决策。
- PET/CT耐受性良好,可在疾病全程准确评估肿瘤范围。
- 18F-Flucyclovine与68Ga-PSMA是临床最常用且最具前景的前列腺癌PET显像剂。
核心结论
- PET/CT是耐受性良好的检查,可在前列腺癌整个临床病史中准确评估肿瘤范围,18F-Flucyclovine与68Ga-PSMA是临床最常用且最具前景的两种显像剂。
研究设计与样本
- 本文为综述,概述18F-Flucyclovine与68Ga-PSMA两种显像剂在老年前列腺癌患者影像中的应用。
主要发现
- 前列腺癌在老年人群中尤为常见,部分治疗方式伴随显著风险或副反应,需准确评估风险获益比。
- 功能影像如PET/CT对临床医生做出适当选择具有重要价值。
- 现有多种前列腺癌PET/CT显像剂,各有特定优缺点。
临床怎么用
- 在老年前列腺癌患者中,可考虑使用PET/CT进行肿瘤范围评估以辅助临床决策。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Due to the increasing life expectancy, the diagnosis of malignancy and treatment of elderly patients is becoming more common. Prostate cancer is particularly frequent in this setting. Many different approaches are now available, but some of them imply significant risks or collateral effects. In those patients an accurate evaluation of risk-to-benefit ratio is needed, and functional imaging such as PET/CT is important for the clinician to make the appropriate choice. PET/CT in prostate cancer is a well-tolerated procedure that can be used to accurately assess the tumor extent during the entire clinical history of the disease. Nowadays there are several available radiopharmaceuticals for prostate cancer PET/CT imaging, each one with specific advantages and disadvantages. The two most promising and more widely employed in the clinical setting are 18F-Flucyclovine and 68Ga-PSMA. This paper will provide an overview of these two tracers for imaging prostate cancer in elderly patients.
引用
- Castellucci P, Nanni C, Ambrosini V, et al. Nuclear Medicine Imaging of Prostate Cancer in the Elderly. Semin Nucl Med. 2018. PMID: 30322480. doi:10.1053/j.semnuclmed.2018.07.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。